{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:15:00Z","timestamp":1771863300865,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["PY3A0241001016"],"award-info":[{"award-number":["PY3A0241001016"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81171490"],"award-info":[{"award-number":["81171490"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.intimp.2020.106258","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T06:59:20Z","timestamp":1581058760000},"page":"106258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Imiquimod-related dermatitis is mainly mediated by mast cell degranulation via Mas-related G-protein coupled receptor B2"],"prefix":"10.1016","volume":"81","author":[{"given":"Yong","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delu","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzhen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiapan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Langchong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songmei","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106258_b0005","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/ijd.13235","article-title":"Imiquimod in dermatology: an overview","volume":"55","author":"Hanna","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2020.106258_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8369690","article-title":"Mediators of inflammation in topical therapy of skin cancers","author":"Voiculescu","year":"2019","journal-title":"Mediators. Inflamm."},{"key":"10.1016\/j.intimp.2020.106258_b0015","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/14656566.2010.481284","article-title":"Treating skin cancer with topical cream","volume":"11","author":"Micali","year":"2010","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.intimp.2020.106258_b0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.det.2004.08.007","article-title":"Imiquimod for the treatment of skin cancer","volume":"23","author":"Burns","year":"2005","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.intimp.2020.106258_b0025","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1046\/j.1365-2133.2000.03777.x","article-title":"Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum","volume":"143","author":"Hengge","year":"2000","journal-title":"Brit. J. Dermatol."},{"key":"10.1016\/j.intimp.2020.106258_b0030","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2015.02.008","article-title":"Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type","volume":"72","author":"Swetter","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2020.106258_b0035","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.survophthal.2019.02.005","article-title":"Current treatment and management of infantile hemangiomas","volume":"64","author":"Satterfield","year":"2019","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.intimp.2020.106258_b0040","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/j.jaad.2013.04.026","article-title":"Successful treatment of verruciform xanthoma with imiquimod","volume":"69","author":"Guo","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2020.106258_b0045","doi-asserted-by":"crossref","first-page":"7332","DOI":"10.1021\/acs.jpcb.8b04001","article-title":"Effect of anti-leishmania drugs on the structural and elastic properties of ultradeformable lipid membranes","volume":"122","author":"Peralta","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.intimp.2020.106258_b0050","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40257-017-0271-3","article-title":"Treatment of porokeratosis: A systematic review","volume":"18","author":"Weidner","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2020.106258_b0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/187221312798889301","article-title":"Imiquimod 5% cream use in dermatology, side effects and recent patents","volume":"6","author":"Cantisani","year":"2012","journal-title":"Recent Patents Inflammat. Allergy Drug Discovery"},{"key":"10.1016\/j.intimp.2020.106258_b0060","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa1811850","article-title":"Randomized trial of four treatment approaches for actinic keratosis","volume":"380","author":"Jansen","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.intimp.2020.106258_b0065","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/14656566.5.2.427","article-title":"Imiquimod as a dermatological therapy","volume":"5","author":"Tran","year":"2004","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.intimp.2020.106258_b0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000453265","article-title":"Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms","volume":"171","author":"Pichler","year":"2016","journal-title":"Int. Arch. Allergy. Immunol."},{"key":"10.1016\/j.intimp.2020.106258_b0075","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0091-6749(84)90107-6","article-title":"Mathews MDAA, Mich. Clinic spectrum of allergic and pseudoallergic drug teactions","volume":"74","author":"Kenneth","year":"1984","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2020.106258_b0080","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.intimp.2016.09.019","article-title":"Targeting mast cells: uncovering prolific therapeutic role in myriad diseases","volume":"40","author":"Singh","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2020.106258_b0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-4939-1173-8_10","article-title":"Measuring histamine and cytokine release from basophils and mast cells","volume":"1192","author":"Jensen","year":"2014","journal-title":"Methods Mol. Biol. (Clifton, NJ)"},{"key":"10.1016\/j.intimp.2020.106258_b0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.106258_b0095","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.intimp.2019.02.001","article-title":"Mast cell-mediated hypersensitivity to fluoroquinolone is mrgprx2 dependent","volume":"70","author":"Liu","year":"2019","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.intimp.2020.106258_b0100","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/eji.201746951","article-title":"Typical antimicrobials induce mast cell degranulation and anaphylactoid reactions via mrgprx2 and its murine homologue mrgprb2","volume":"47","author":"Zhang","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2020.106258_b0105","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/1346-8138.13821","article-title":"Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod","volume":"44","author":"Oyama","year":"2017","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2020.106258_b0110","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1111\/1346-8138.14642","article-title":"Epidermal mast cells in bowenoid papulosis during topical imiquimod therapy","volume":"46","author":"Miura","year":"2019","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2020.106258_b0115","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.bbrc.2017.04.141","article-title":"Th17 cell-mediated immune responses promote mast cell proliferation by triggering stem cell factor in keratinocytes","volume":"487","author":"Cho","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2020.106258_b0120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.intimp.2018.07.020","article-title":"Cisatracurium induces mast cell activation and pseudo-allergic reactions via mrgprx2","volume":"62","author":"Che","year":"2018","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.intimp.2020.106258_b0125","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2006-07-036889","article-title":"Mast cells are crucial for early inflammation, migration of langerhans cells, and ctl responses following topical application of tlr7 ligand in mice","volume":"110","author":"Heib","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2020.106258_b0130","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2006.08.177","article-title":"Immunoglobulin e-independent activation of mast cell is mediated by mrg receptors","volume":"349","author":"Tatemoto","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"622\u2013633","key":"10.1016\/j.intimp.2020.106258_b0135","article-title":"Expression of mas-related gene x2 on mast cells is upregulated in the skin of patients with severe chronic urticaria","volume":"134","author":"Fujisawa","year":"2014","journal-title":"J. Allergy. Clin. Immunol."},{"key":"10.1016\/j.intimp.2020.106258_b0140","article-title":"Brief communication: Mrgprx2, atopic dermatitis and red man syndrome","volume":"2","author":"Azimi","year":"2017","journal-title":"Itch. (Philadelphia. Pa)"},{"key":"10.1016\/j.intimp.2020.106258_b0145","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/cod.13292","article-title":"All-trans-retinoic acid activated mast cells via mas-related g-protein-coupled receptor-x2 in retinoid dermatitis","volume":"81","author":"Zheng","year":"2019","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.intimp.2020.106258_b0150","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1172\/JCI61034","article-title":"Imiquimod clears tumors in mice independent of adaptive immunity by converting pdcs into tumor-killing effector cells","volume":"122","author":"Drobits","year":"2012","journal-title":"J. Clin. Investig."},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2020.106258_b0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: Mode of action","volume":"157","author":"Sch\u00f6n","year":"2007","journal-title":"Brit. J. Dermatol."},{"key":"10.1016\/j.intimp.2020.106258_b0160","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/eji.201343801","article-title":"Tlrs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis","volume":"43","author":"Flutter","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2020.106258_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030739","article-title":"Advances in understanding the immunological pathways in psoriasis","volume":"20","author":"Georgescu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2020.106258_b0170","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.intimp.2017.05.016","article-title":"Ll-37-induced human mast cell activation through g protein-coupled receptor mrgx2","volume":"49","author":"Yu","year":"2017","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.intimp.2020.106258_b0175","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejphar.2011.06.027","article-title":"G protein coupled receptor specificity for c3a and compound 48\/80-induced degranulation in human mast cells: Roles of mas-related genes mrgx1 and mrgx2","volume":"668","author":"Kashem","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2020.106258_b0180","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/imr.12629","article-title":"Non-ige mediated mast cell activation","volume":"282","author":"Redegeld","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2020.106258_b0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/imr.12634","article-title":"Mast cells as sources of cytokines, chemokines, and growth factors","volume":"282","author":"Mukai","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2020.106258_b0190","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","article-title":"Highly effective new treatments for psoriasis target the il-23\/type 17 t cell autoimmune axis","volume":"68","author":"Kim","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.intimp.2020.106258_b0195","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/17460441.2018.1463214","article-title":"Murine models of psoriasis and their usefulness for drug discovery","volume":"13","author":"Chuang","year":"2018","journal-title":"Expert. Opin. Drug. Discov."},{"issue":"182","key":"10.1016\/j.intimp.2020.106258_b0200","first-page":"5836","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the il-23\/il-17 axis","volume":"2009","author":"van der Fits","year":"1950","journal-title":"J. Immunol. (Baltimore, Md)"},{"key":"10.1016\/j.intimp.2020.106258_b0205","first-page":"368","article-title":"Density of mast cells and intensity of pruritus in psoriasis vulgaris: a cross sectional study","volume":"93","author":"Peres","year":"2018","journal-title":"Anais brasileiros de dermatologia"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919322192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919322192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:22:03Z","timestamp":1761585723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919322192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":41,"alternative-id":["S1567576919322192"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106258","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imiquimod-related dermatitis is mainly mediated by mast cell degranulation via Mas-related G-protein coupled receptor B2","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106258"}}